We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-1.1%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.36B
AUM Growth
-$17.8M
Cap. Flow
+$178M
Cap. Flow %
5.3%
Top 10 Hldgs %
63.12%
Holding
56
New
4
Increased
15
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$120M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.1M
3
FATE icon
Fate Therapeutics
FATE
+$33.5M
4
ADPT icon
Adaptive Biotechnologies
ADPT
+$23.6M
5
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$22.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$39.6M
2
BNR
Burning Rock Biotech
BNR
+$32.7M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.5M
4
RLAY icon
Relay Therapeutics
RLAY
+$18.8M
5
ADVM
Adverum Biotechnologies
ADVM
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 86.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
1
DELISTED
Invitae Corporation
NVTA
$466M 13.89%
12,203,669
-94,369
-0.8% -$4.29M
EXAS
2
DELISTED
Exact Sciences
EXAS
$311M 9.26%
2,360,186
+875,037
+59% +$120M
FATE icon
3
Fate Therapeutics
FATE
$294M
$280M 8.35%
3,400,000
+350,000
+11% +$33.5M
BLFS icon
4
BioLife Solutions
BLFS
$1.56B
$268M 7.98%
7,440,107
– –
PACB icon
5
Pacific Biosciences
PACB
$444M
$167M 4.96%
5,000,000
– –
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$151M 4.49%
1,550,000
– –
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$29.1B
$124M 3.7%
880,000
+100,000
+13% +$15M
TWST icon
8
Twist Bioscience
TWST
$5.97B
$124M 3.69%
1,000,000
– –
RLAY icon
9
Relay Therapeutics
RLAY
$4.04B
$117M 3.48%
3,375,058
-433,836
-11% -$18.8M
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.84B
$112M 3.33%
2,165,000
-210,000
-9% -$10.4M
CDXS icon
11
Codexis
CDXS
$157M
$99.1M 2.95%
4,330,000
– –
DNLI icon
12
Denali Therapeutics
DNLI
$3.67B
$91.9M 2.74%
1,610,000
+300,000
+23% +$20.1M
DMTK
13
DELISTED
DermTech, Inc. Common Stock
DMTK
$88.6M 2.64%
1,745,000
+375,000
+27% +$19.6M
RVMD icon
14
Revolution Medicines
RVMD
$38.8B
$84.6M 2.52%
1,844,535
+210,000
+13% +$9.42M
CDNA icon
15
CareDx
CDNA
$2.48B
$81.3M 2.42%
1,193,335
– –
BEAM icon
16
Beam Therapeutics
BEAM
$2.66B
$65.5M 1.95%
818,820
+358,820
+78% +$34.1M
ONC
17
BeOne Medicines Ltd
ONC
$32.3B
$52.2M 1.56%
150,000
– –
ADPT icon
18
Adaptive Biotechnologies
ADPT
$3.71B
$46.3M 1.38%
1,150,000
+436,875
+61% +$23.6M
ALLO icon
19
Allogene Therapeutics
ALLO
$632M
$45.9M 1.37%
1,300,000
+355,000
+38% +$12M
GBIO
20
DELISTED
Generation Bio
GBIO
$45.9M 1.37%
161,121
– –
FDMT icon
21
4D Molecular Therapeutics
FDMT
$524M
$43.2M 1.29%
995,354
+214,799
+28% +$9.51M
CNST
22
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$42.1M 1.25%
1,800,000
+15,000
+0.8% +$454K
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.63B
$41M 1.22%
550,000
+20,000
+4% +$1.85M
DNTH icon
24
Dianthus Therapeutics
DNTH
$5.72B
$39.6M 1.18%
209,127
– –
GBT
25
DELISTED
Global Blood Therapeutics, Inc.
GBT
$36.7M 1.09%
900,000
+90,000
+11% +$4.14M
1
2 3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Casdin Capital held 56 positions worth $3.36B, down 0.53% from $3.38B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Casdin Capital deployed $178M of net new capital in Q1 2021, opening 4 new positions and adding to 15 existing holdings. Its largest new stake was Orchard Therapeutics plc American Depositary Shares: 321,543 shares worth $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Burning Rock Biotech, an estimated $32.7M trimmed.

  • Casdin Capital's largest Q1 2021 buy was Orchard Therapeutics plc American Depositary Shares: 321,543 shares worth $23.3M.
  • Casdin Capital added most to Exact Sciences in Q1 2021, an estimated $120M increase.
  • Casdin Capital's biggest Q1 2021 reduction was Burning Rock Biotech, cutting an estimated $32.7M.
  • Casdin Capital fully exited bluebird bio in Q1 2021, selling an estimated $39.6M.
  • Casdin Capital's ten largest holdings make up 63% of its $3.36B portfolio in Q1 2021.
  • Casdin Capital opened 4 new positions and closed 8 in Q1 2021.
  • Casdin Capital's portfolio value fell 0.53% quarter-over-quarter to $3.36B.

Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.